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Beclin-1 expression is retained in high-grade
serous ovarian cancer yet is not essential for
autophagy induction in vitro
Rohann J. M. Correa1,2, Yudith Ramos Valdes1, Trevor G. Shepherd1,3,4,5† and Gabriel E. DiMattia1,2,3,4,6*†
Abstract
Background: Autophagy is a conserved cellular self-digestion mechanism that can either suppress or promote
cancer in a context-dependent manner. In ovarian cancer, prevalent mono-allelic deletion of BECN1 (a canonical
autophagy-inducer) suggests that autophagy is impaired to promote carcinogenesis and that Beclin-1 is a
haploinsufficient tumor suppressor. Nonetheless, autophagy is known to be readily inducible in ovarian cancer cells.
We sought to clarify whether Beclin-1 expression is in fact disrupted in ovarian cancer and whether this impacts
autophagy regulation.
Methods: BECN1 expression levels were assessed using The Cancer Genome Atlas (TCGA) datasets from 398 ovarian
high-grade serous cystadenocarcinomas (HGSC) and protein immunoblot data from HGSC samples obtained at our
institution. Knockdown of BECN1 and other autophagy-related gene expression was achieved using siRNA in
established human ovarian cancer cell lines (CaOV3, OVCAR8, SKOV3, and HeyA8) and a novel early-passage, ascites-
derived cell line (iOvCa147-E2). LC3 immunoblot, autophagic flux assays, transmission electron microscopy and
fluorescence microscopy were used to assess autophagy.
Results: We observed prevalent mono-allelic BECN1 gene deletion (76 %) in TCGA tumors, yet demonstrate for the first
time that Beclin-1 protein expression remains relatively unaltered in these and additional samples generated at our
institution. Surprisingly, efficient siRNA-mediated Beclin-1 knockdown did not attenuate autophagy induction, whereas
knockdown of other autophagy-related genes blocked the process. Beclin-1 knockdown instead decreased cell viability
without inducing apoptosis.
Conclusions: Taken together, these data demonstrate that despite its sustained expression, Beclin-1 is dispensable for
autophagy induction in ovarian tumor cells in vitro, yet may be retained to promote cell viability by a mechanism
independent of autophagy or apoptosis regulation. Overall, this work makes novel observations about tumor
expression of Beclin-1 and challenges the accepted understanding of its role in regulating autophagy in ovarian cancer.
Keywords: High-grade serous ovarian cancer, Spheroid, Autophagy, Beclin-1
Background
Macroautophagy (autophagy) is a conserved mechan-
ism for the sequestration of cytoplasmic contents in
membrane-bound vesicles and their subsequent lysosome-
mediated degradation. It facilitates turnover of damaged
organelles, removal of misfolded/aggregated proteins, and
destruction of intracellular pathogens, ridding the cell
of harmful components [1] and liberating constituent
biomolecules to fuel metabolic and biosynthetic path-
ways [2]. In this way, autophagy plays an essential role
in maintaining cellular homeostasis.
Autophagy is negatively regulated by growth-factor
signaling through the PI3K/AKT pathway – specifically
by the downstream activity of mechanistic target of
Rapamycin complex 1 (mTORC1). If mTORC1 activity
is suppressed, however, an autophagy-inducing complex
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is allowed to form and convey activating signals to
downstream effectors [3]. These effectors are mamma-
lian homologues of autophagy-related (“atg”) proteins
originally discovered in yeast [4]. They play pivotal roles
in the initiation of autophagic membrane formation,
deployment of these membranes to envelop cytoplasmic
contents, and the delivery of this cargo to lysosomes for
degradation [5].
Among the ATGs, BECN1 (mammalian homologue of
yeast atg6 that encodes Beclin-1) was one of the earliest
discovered and has been extensively studied. It functions
in a core complex with Class III PI3K (PI3K C3) [6] and
p150 [7] as a canonical initiator of autophagy [8]. Mice
harboring heterozygous disruption of the Becn1 gene
(Becn1+/−) are viable but develop malignancies at higher
rates than wild-type littermates [9]. Moreover, the human
chromosomal BECN1 locus (17q21) exhibits single-copy
loss in prostate [10] and breast cancers [11, 12]. In ovarian
cancer, heterozygous loss is most prevalent, affecting up
to 70 % of tumors [13–17]. Therefore, Beclin-1 – and
autophagy by extension – are thought to be tumor
suppressive.
Although homeostatic autophagy in normal tissues
may initially curtail tumorigenesis, evidence exists for
autophagy upregulation in established tumors [18]. This
may serve as an adaptive response to mitigate cellular
stresses that typify tumor pathobiology, including intrin-
sic stresses such as high metabolic demands [19] and
ER-stress [20] as well as extrinsic stresses such as anti-
neoplastic agents [21] and the tumor microenvironment
itself [e.g., hypoxia [22], reduced nutrient [23] and growth
factor availability [24]]. In ovarian cancer, autophagy
induction was classically demonstrated by Lu et al. in
2008 [25] and in numerous other studies since then,
including our own work [26]. Most recently, increased
autophagy in recurrent tumor nodules on the periton-
eal surface relative to patient-matched primary ovarian
tumors has been described, suggesting that autophagy
is important the setting of ovarian cancer metastasis
[27].
Since ovarian tumors appear capable of undergoing
autophagy despite prevalent BECN1 heterozygous loss,
we wondered if Beclin-1 was actually downregulated in
this context and whether it was still required for autoph-
agy induction. Here we demonstrate that even with
prevalent BECN1 single-copy loss, Beclin-1 protein ex-
pression remains similar across 398 high-grade serous
ovarian tumors. Yet surprisingly, knockdown of Beclin-1
had no effect on autophagy induced by either pharmaco-
logic or non-pharmacologic stimuli. It did, however,
reduce cell viability in an apoptosis-independent manner
in two cell lines tested. Therefore, Beclin-1 appears non-
essential for autophagy induction in ovarian cancer
in vitro cultures. Nonetheless, its sustained expression
may contribute to cell viability by a currently undefined
mechanism.
Materials & methods
Isolation of tumor cells from patient tissues
All work with patient materials has been approved by
the Western University Health Sciences Research Ethics
Board (Protocol numbers 12668E and 16391E). The ma-
jority of samples were collected from patients with stage
II-IV high-grade serous ovarian carcinoma (Additional
file 1: Table S1). Ascitic fluid collected at time of para-
centesis or debulking surgery was used to generate pri-
mary ascites cell cultures as described previously [28].
Solid tumor tissue from metastatic lesions was obtained
at time of debulking surgery. Briefly, tissue was dissected
into cubes ~2-5 mm2 in size, wrapped in aluminum foil,
snap-frozen on dry ice, and stored at −80 °C. To gener-
ate lysates, samples removed from −80 °C were mixed
with dry ice pellets and pulverized using a mortar and
pestle. The powdered sample was then added to lysis
buffer and lysates prepared as previously described [26].
Culture of ovarian cancer cell lines
Human ovarian cancer cell lines were purchased from the
American Type Culture Collection (ATCC; Manassas,
VA) and cultured in Dulbecco's modified Eagle's medium
(SKOV3, CaOV3) or RPMI-1640 (OVCAR8, HeyA8)
supplemented with 5 % fetal bovine serum (FBS; Wisent).
Early-passage cell lines (designated “iOvCa”) are derived
from ascites cultures (designated “EOC”) of the corre-
sponding number (e.g., iOvCa201 is a line derived from
EOC201). Early-passage lines were maintained in DMEM/
F12 medium (Gibco/Invitrogen, Carlsbad, CA) supple-
mented with 10 % FBS. The iOvCa147-E2 line is a clone
of iOvCa147. To establish stable expression of eGFP-
LC3B, sub-confluent (~60-70 %) OVCAR8 cells were
transfected with the pBMN-ires-puro-eGFP-LC3B con-
struct (gift of Dr. C. McCormick, Dalhousie University) and
transferred to Puromycin-containing selection medium
(1 μg/mL) where clones with robust eGFP-LC3B expres-
sion were isolated. All cells were maintained in a 37 °C hu-
midified atmosphere of 95 % air and 5 % CO2. Adherent
cells were maintained on tissue culture-treated polystyrene
(Sarstedt, Newton, NC) and non-adherent cells were
maintained on Ultra-low Attachment (ULA) cultureware
(Corning, Corning, NY).
Immunofluorescence and immunoblotting
Spheroids present in ascitic fluid at time of collection
were isolated by filtration through a 40 μm cell-strainer
(Becton Dickinson, Franklin Lakes, NJ), gently rinsed
off the membrane with PBS into a collection tube, em-
bedded in cryo-matrix (Fisher, Ottawa, ON), and frozen
on dry ice for storage at −80 °C. Frozen blocks were
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sectioned on a Shandon cryostat at 6 μm, mounted on
slides, and stored at −20 °C until needed. Spheroid sec-
tions were processed, stained, microscopy performed,
and images captured as was done previously for adher-
ent cells on coverslips [26]. Anti-LC3 antibody (1:250;
Cell Signaling Technology, Danvers, MA) was used to
stain endogenous autophagosome-associated fluorescent
puncta.
For immunoblotting, all samples (cultured cells or
tumor tissue) were lysed in a supplemented RIPA buffer
prepared as previously described [26]. Protein concen-
tration was determined using Bradford’s method, immu-
noblots performed, chemiluminescent images captured,
and band intensities quantified all as previously de-
scribed [26].
Antibodies and other reagents
Antibodies against pAkt-Ser473 (#9271), AKT (#9272),
p-p70S6K (#9234), p70S6K (#2708), LC3 (#2775), Beclin-1
(#3738), Atg5 (#2855), and Atg7 (D12B11; #8558) were
obtained from Cell Signaling Technology (Danvers, MA).
Anti-actin antibody (A 2066) was purchased from Sigma.
Akt inhibitor VIII (Akti-1/2) was purchased from EMD/
Calbiochem (#12408; SanDiego, CA) and Chloroquine was
purchased from Sigma (C-6628).
Transmission electron microscopy
Adherent cells (80 % confluent) or spheroids (24 h fol-
lowing seeding to non-adherent culture) were collected,
fixed, dehydrated, embedded in resin, sectioned, stained,
and examined using transmission electron microscopy
as previously described [26].
Acquisition of The Cancer Genome Atlas (TCGA), Cancer
Cell Line Encyclopedia (CCLE), and The Cancer Proteome
Atlas (TCPA) datasets
Copy-number data for ovarian serous cystadenocarcinoma
samples were generated from array comparative genomic
hybridization data acquired at the Broad TCGA genome
characterization center using the Affymetrix Genome-Wide
Human SNP Array 6.0 platform. Raw data were analyzed
using the GISTIC2 method to generate gene-level
copy-number calls and downloaded from Memorial
Sloan-Kettering Cancer Center’s cBioPortal for Cancer
Genomics (http://www.cbioportal.org/) [29]. GISTIC2-
generated copy-number estimates (log2-transformed
values, not thresholded) were downloaded from the UCSC
Cancer Browser (https://genome-cancer.ucsc.edu). Copy-
number data for Cancer Cell Line Encyclopedia (CCLE)
ovarian cancer lines were also generated using GISTIC2
and downloaded as copy number calls from cBioPortal.
Protein expression data was generated at the MD
Anderson Cancer Center (MDACC) TCGA proteome
characterization center using reverse-phase protein array
(RPPA) technology and were normalized to sample
medians as previously described [30]. RPPA data were
downloaded as z-scores from the cBioPortal and as log2-
normalized values from the UCSC Cancer Browser.
RPPA datasets for CCLE ovarian cancer lines (batch 35)
were obtained from MDACC’s TCPA website (http://
app1.bioinformatics.mdanderson.org/tcpa/_design/basic/
index.html).
Copy-number and RPPA datasets were last downloaded
on July 3, 2014.
siRNA transfection
For RNAi-mediated knockdown of gene expression, we
utilized Dharmacon siGENOME SMARTpool reagents
[Non-Targeting Control Pool #2 (D-001206-14-05),
BECN1 (M-010552-01), ATG5 (M-004374-04), and ATG7
(M-020112-01); Thermo Scientific, Waltham, MA].
Transfections were conducted according to manufac-
turer’s instructions with modifications described previ-
ously [26]. Importantly, double-transfection was used
as described by Smith et al., to maximize efficiency
and duration of knockdown [31]. iOvCa147-E2 cells
were seeded to 6-well plates at a density of 350,000/well
whereas the density for CaOV3, OVCAR8, SKOV3, and
HeyA8 cells were 200,000/well. Cells were counted and
seeded for further experimentation 96 h following initial
transfection.
Assays of cell viability and apoptosis
Adherent culture: 96 h post-transfection, adherent cells
were trypsinized and single-cell suspensions generated
for cell counting. To enumerate viable cells, Trypan Blue
reagent (Gibco/Invitrogen, Carlsbad, CA) was applied
(1:1 dilution) and cells counted in a using a TC-10
automated cell counter (BioRad, Mississauga, ON) with
two counts per replicate of experimental triplicates.
Spheroid culture: 96 h post-transfection, cells were
trypsinized, counted and seeded to 24-well ultra-low
attachment plates at a density of 5.0x104 per well to
form spheroids as previously described. Spheroids were
collected, pelleted, and briefly loosened/disaggregated by
trypsinization (~5 min) 72 h post-seeding. CellTiter-Glo
reagent (Promega, Madison, WI) was prepared accord-
ing to manufacturer’s instructions and added to spher-
oids in trypsin (1:1 volume ratio). The mixture was
transferred to a white-walled 96-well microplate and
luminescence detected in triplicate wells using a spec-
trophotometer (Wallac 1420 Victor 2; Perkin-Elmer,
Waltham, MA).
To assess apoptosis, the Caspase-Glo 3/7 assay (Pro-
mega, Madison, WI) was used as per manufacturer’s in-
structions (1:1 volume ratio). Reagent was added directly
to 96-well tissue culture plates containing adherent cells.
Spheroids were first collected, centrifuged, and media
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aspirated until 100 μL remained and then equal volume of
reagent added. Following 1.5 h incubation, the mixture
was transferred to a white-walled 96-well microplate and
luminescence measured using a microplate spectropho-
tometer (Wallac 1420 Victor 2; Perkin-Elmer, Waltham,
MA). Measurements were made in triplicate wells. Add-
itionally, a Human Apoptosis Antibody Array (R&D Sys-
tems, Minneapolis, MN) was used to screen for alteration
in protein expression of 35 apoptosis-associated genes.
Adherent and spheroid cells were collected and lysed at
24 h post-seeding using the supplied buffer, protein
concentration quantified using Bradford’s method, and
samples treated as per manufacturer’s instructions.
Chemiluminescent images were captured and signal
intensity quantified as previously described [26].
Graphing and statistical analysis
All graphs were generated using GraphPad Prism 5
(GraphPad Software, San Diego, CA). Data were expressed
as Mean ± SD or Mean ± SEM, as indicated. All statistical
analyses [Student’s t-test, Analysis of Variance (ANOVA)
with Newman-Keuls correction for multiple compari-
sons, as well as correlation and linear regression] were
performed using GraphPad Prism 5. Tests of signifi-
cance were set at p < 0.05.
Results
Despite prevalent single-copy loss of the BECN1 gene,
Beclin-1 protein expression is maintained in high-grade
serous ovarian tumors and ascites-derived cells
Heterozygous loss of the canonical autophagy gene
BECN1 is well documented in epithelial ovarian cancer
cells [13–17]. To our knowledge, however, no study has
yet determined whether hemizygosity at the BECN1
locus results in correspondingly decreased expression at
the protein level in ovarian tumors.
In order to assess the relationship between BECN1
copy-number and expression, we interrogated level 3
array comparative genomic hybridization (aCGH) and
RPPA data generated by TCGA from a large number of
high-grade serous ovarian tumors (91 % of which are
from metastatic, stage III-IV disease; Additional file 2:
Table S2). Based on aCGH data that was processed to
yield gene-level copy-number calls, 433/569 ovarian
tumours (76 %) possessed hemizygous deletion of the
BECN1 gene (Fig. 1a). This confirms earlier reports of
single-copy loss in ~70 % of tumors [10, 14–16].
To determine whether BECN1 copy-number corre-
lated with protein expression, we first plotted RPPA z-
scores from 398 tumors against their copy-number calls.
Interestingly, only 9 tumors with hemizygous BECN1
loss had Beclin-1 expression lower than 2 standard devi-
ations from the mean (z-score of −2; Fig. 1b). Moreover,
we did not find a significant reduction in Beclin-1
protein abundance associated with decreased copy-
number (p > 0.05). We also plotted normalized RPPA
values against log2-transformed copy-number. Again,
largely equivocal Beclin-1 expression was observed in
samples regardless of gene copy-number (Fig. 1c), how-
ever linear regression and correlation analyses did re-
veal a weak (r = 0.10; R2 = 0.01) yet significant (p = 0.0455)
correlation between copy-number and protein expression.
Nonetheless, these data clearly demonstrate that in most
tumors harboring single-allele loss of BECN1, its protein
product is still expressed at approximately diploid levels.
Furthermore, metastatic tumor samples (Fig. 1d),
primary ascites cell cultures (Fig. 1e), and early-passage
cell lines generated at our institute (Fig. 1f ) exhibited a
similar trend in Beclin-1 protein expression. Samples
identified as the highest- and lowest-expressers were
assessed on the same immunoblot, demonstrating only
modest differences in protein abundance analogous to
the narrow range of expression observed in TCGA
samples (Fig. 1c).
Collectively, these data show that the level of Beclin-1
protein in epithelial ovarian cancer specimens falls
within an easily detectable narrow range regardless of
copy number.
Autophagy is inducible in ascites cells derived from
patients with high-grade serous ovarian cancer (HGSC)
We previously demonstrated that ascites-derived cells
cultured as adherent monolayers or multicellular aggregates
(spheroids) induced cyto-protective autophagy in response
to AKT inhibition, a well-known stimulus for autophagy
induction [26]. Closer examination of these data led us to
suspect that spheroid culture itself might serve as a
sufficient stimulus for autophagy.
To investigate this possibility, ascites fluid was collected
from consenting patients with HGSC. These samples
contain tumor cells in suspension that exist either as single
cells or spheroids, the latter being considered an integral
part of ovarian cancer metastasis (reviewed in [32]). Frozen
sections of isolated spheroids were generated and immuno-
fluorescence staining performed for microtubule-associated
light-chain 3 (LC3), the most established marker of autoph-
agy. This revealed LC3 protein localization to discrete
puncta throughout the cytoplasm of spheroid-associated
cells (Fig. 2a), consistent with the presence of autophagic
vesicles or autophagosomes.
To further characterize spheroid-associated autophagy,
ascites cell cultures (EOCs) were established from multiple
patients, then transferred to non-adherent cultureware to
generate in vitro spheroids as previously described [33].
Protein lysates of these cultures were generated for the
indicated time-points and immunoblots performed for
LC3, since its cleaved and lipidated form (LC3-II) is identi-
fiable as a differentially migrating species that indicates the
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presence of autophagosomes. We observed a significant
increase in abundance of LC3-II as early as 4 h post-
seeding (p < 0.01), with the ratio of LC3-II:LC3-I greatest by
approximately 24 h (once aggregates/spheroids have
formed; Fig. 2b). This increased LC3-II:LC3-I ratio was
maintained through 72 h of non-adherent culture des-
pite a decrease in the absolute amounts of these species
over that time, a phenomenon known to occur with ex-
tended autophagy (Fig. 2b). In addition to time-course
analysis, we also assessed paired adherent/spheroid
Fig. 1 Beclin-1 protein expression is maintained in high-grade serous ovarian tumors and ascites-derived cells. a Gene copy-number calls at the
BECN1 locus are depicted for 569 ovarian serous cystadenocarcinoma tumors (teal & blue = heterozygous & homozygous deletion, respectively;
red & pink = high-level & low-level amplification, respectively). OncoPrint generated using cBioPortal.org. b BECN1 protein expression data (RPPA)
expressed as z-scores and GISTIC2-based copy-number calls for 398 samples were downloaded from cBioPortal and plotted. One-way ANOVA
with Tukey’s Test was performed (NS: p > 0.05). Lines: Mean ± SEM. c Log2-transformed and normalized RPPA data and GISTIC2-based
copy-number estimates (log2-transformed) for 398 samples were downloaded from UCSC’s Cancer Browser and plotted. d-f Beclin-1 expression
was quantified in fresh-frozen samples of metastatic tumor tissue (d), primary cultures of ascites-derived cells (e), and early-passage
ascites-derived cell lines (f). Quantification was performed using densitometry and depicted relative to Actin
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Fig. 2 (See legend on next page.)
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samples generated from ten EOC cultures, verifying sig-
nificantly increased LC3-II relative to LC3-I at both the
24 h and 72 h time points (p < 0.05; Fig. 2c).
To verify that autophagy was proceeding through the
degradation phase in spheroids (i.e., lysosomes fusing with
autophagosomes), they were subjected to transmission
electron microscopy (TEM). Ultra-thin sections of fixed
spheroid cells were examined for autophagolysosomes
(APLs): cytoplasmic vesicles bounded by double-
membranes whose contents are undergoing degrad-
ation. APLs were not observed in adherent cultures
(Fig. 2d, a-b), but were frequently noted in spheroids
(Fig. 2d, c-h), suggesting that autophagy is induced
and proceeds to the degradation phase in spheroid
cells.
Finally, we compared spheroid-associated autophagy
to pharmacologically-induced autophagy (treatment with
Akti-1/2, an allosteric AKT inhibitor) that we demon-
strated in our prior report [26]. Inhibition of AKT
activity reduces mTORC1 activity allowing induction of
autophagy. As evidenced by LC3 processing, spheroid-
associated autophagy was comparable to that induced by
Akti-1/2 in parallel adherent cultures (Fig. 2e). This was
observed in primary ascites cell cultures (EOCs) as well
as the early-passage cell line iOvCa147-E2 (derived from
an ascites culture). Therefore, ascites-derived cells easily
induce autophagy by both pharmacologic as well as
spheroid-associated, non-pharmacologic means.
Autophagy is induced in established ovarian cancer cell
lines irrespective of endogenous Beclin-1 expression level
or gene copy number
To further investigate the contribution of Beclin-1
expression to autophagy induction in ovarian cancer,
representative lines with low, intermediate, and high
Beclin-1 expression were selected based on datasets
from the Cancer Cell Line Encyclopedia (CCLE) project
[34]. BECN1 copy-number and mRNA expression level
were plotted for 51 ovarian cancer cell lines (Fig. 3a).
From this, commonly-used lines were chosen for further
analysis based on BECN1 gene copy-number (SKOV3,
amplification; HeyA8 and OVCAR8, low-level gain;
CaOV3, heterozygous loss) and mRNA expression
(CaOV3, low; OVCAR8, intermediate; SKOV3 and
HeyA8, high). Quantitative protein expression data for
these cell lines (obtained from The Cancer Proteome
Atlas, TCPA) was in agreement with mRNA expres-
sion data (Fig. 3b). Likewise, in our hands, these four
lines each expressed significantly different levels of
Beclin-1 protein (Fig. 3c, d).
Despite differences in Beclin-1 expression and gene
copy-number, all four lines were able to induce autophagy.
In adherent cells, 24 h treatment with Akti-1/2 resulted in
enhanced processing of LC3 protein and an increased
abundance of LC3-II relative to untreated cells (Additional
file 3: Figure S1A). The addition of a Chloroquine (CQ;
50 μM) pulse in the final 4 h preceding lysis resulted in a
further increase in LC3-II in all three lines as expected
given that CQ will stall autophagosome processing leading
to a further increase in the LC3-II isoform (Additional
file 3: Figure S1A), thus confirming autophagic flux. In
non-adherent spheroids, the addition of a CQ pulse
also increased LC3-II levels, likewise implying flux of
spheroid-associated autophagy (Additional file 3: Figure
S1B). Similar results were obtained in the early-passage,
ascites-derived line iOvCa147-E2 (Additional file 3:
Figure S1A,B), which possesses lower Beclin-1 expres-
sion compared with other iOvCa lines (Fig. 1f ). Thus,
representative ovarian cancer cell lines of low, inter-
mediate, and high endogenous Beclin-1 expression are
able to robustly induce autophagy.
Efficient Beclin-1 knockdown does not block autophagy
induction in ovarian cancer cell lines
We have demonstrated that ovarian tumors and cell lines
maintain Beclin-1 protein expression, and that in vitro
cultures of these cells retain the capacity to upregulate
autophagy. To directly test the contribution of Beclin-1 to
autophagy, we used RNA interference to knock down its
expression.
Rather than a single siRNA targeting BECN1, we chose
to use a ‘SMARTpool’ of siRNAs in an attempt to ensure
efficient knockdown. Transfection with siRNAs against
BECN1 efficiently reduced its protein level in CaOV3,
OVCAR8, and HeyA8 cells. Expression of the canonical
autophagy regulatory proteins ATG5 and ATG7 was also
(See figure on previous page.)
Fig. 2 Autophagy is readily inducible in ascites-derived cells. a Spheroids filtered from patient ascites fluid for immunofluorescence analysis
(n = 3 EOC samples). Nuclei (blue) and cytoplasmic LC3 staining (green) are visible. Orange arrowheads indicate LC3 puncta. Scale Bar: 20 μm. b
EOC cells were seeded to non-adherent plates and lysates obtained at indicated time points. Immunoblot of EOC67 (top) and quantification of
LC3-I and LC3-II expression relative to Actin (n = 3 EOC samples) were performed. Bars: Mean ± SEM; *p < 0.05, **p < 0.01. c. Quantifications also
performed on immunoblots of parallel adherent (ADH) and (SPH) cultures of multiple EOC samples (n = 10) at 24 h (top) and 72 h (bottom). Bars:
Mean ± SEM; *p < 0.05. d Parallel adherent (~80 % confluent) and spheroid cultures were analyzed by transmission electron microscopy. Orange
arrowheads denote autolysosomes (autophagosomes that have fused with lysosomes). Scale bars: 500 nm. e Adherent (ADH) cultures
(~80 % confluent) of the indicated samples were subjected to 24 h of Akti-1/2 treatment (EOCs: 5 μM; iOvCa147-E2: 3.5 μM) and protein lysates
generated. Parallel spheroid cultures (24 h under non-adherent conditions) of the indicated samples were also simultaneously lysed and
immunoblot performed for indicated proteins
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efficiently reduced using RNA interference (Fig. 4). In
adherent cells, knockdown significantly reduced levels of
Beclin-1 protein, but this had no effect on Akti-1/2-me-
diated autophagy upregulation as LC3-II accumulation
was not correspondingly blocked. This phenomenon was
observed in all lines tested: CaOV3, OVCAR8, HeyA8
(Fig. 4a) as well as SKOV3 (Additional file 4: Figure S2A).
Replicate immunoblots were quantified and statistically
analyzed, demonstrating significant Beclin-1 knockdown
(p < 0.001) but unchanged LC3-II (Additional file 5: Figure
S3A). In contrast, knockdown of ATG5, ATG7, or their
combination, effectively blocked LC3-II accumulation as
expected (Fig. 4a). In SKOV3 cells, only knockdown of
ATG7 effectively blocked LC3-II accumulation (Additional
file 4: Figure S2A).
Similar results were seen during spheroid formation,
whereby Beclin-1 knockdown failed to block autophagy
upregulation. This was observed in CaOV3, OVCAR8,
and HeyA8 (Fig. 4b) as well as SKOV3 cells (Additional
file 4: Figure S2B). Replicate immunoblots were quantified
and analyzed, confirming significant Beclin-1 knockdown
(p < 0.05) but unchanged LC3-II (Additional file 5:
Figure S3A). Nonetheless, spheroid-induced autophagy
was effectively blocked upon knockdown of ATG5, ATG7,
or both, as evidenced by suppression of LC3-II (Fig. 4b).
In SKOV3 cells, only knockdown of ATG7 was able to
suppress LC3-II (Additional file 4: Figure S2B).
To extend these analyses and provide an alternate
method for monitoring autophagy, OVCAR8 cells were
generated to stably express an eGFP-labeled LC3B
protein. Upon autophagy induction, the cytoplasmic
distribution of this fusion protein shifts from a diffuse
to punctate appearance as it is incorporated into forming
autophagosomes, thus providing visual confirmation that
the process is underway [35]. OVCAR8-eGFP-LC3 cells
were treated with Akti-1/2 to induce autophagy, prompt-
ing a clear shift from diffuse to punctate fluorescence
compared to cells treated with vehicle control (Fig. 5a).
Knockdown of ATG5, ATG7, or their combination under
the same autophagy-inducing conditions resulted in
Fig. 3 In established ovarian cancer cell lines, BECN1 copy-number correlates with mRNA and protein expression. a Log2-transformed mRNA
expression data for 52 ovarian cancer cell lines [Cancer Cell Line Encyclopedia (CCLE) datasets] are displayed as a function of BECN1 copy number
calls. Cell lines representative of low (CaOV3), intermediate (OVCAR8), and high (SKOV3, Hey A8) Beclin-1 expression were selected for further
analysis. b Beclin-1 protein expression is depicted for the selected cell lines [normalized linear Reverse-Phase Protein Array (RPPA) values from
The Cancer Proteome Atlas (TCPA) datasets]. c Independent protein lysates from adherent cultures (n = 3) were run on a single gel with
representative lanes depicted for each cell line (intervening lanes cropped). d Beclin-1 expression was quantified relative to Actin. Bars: Mean
± SEM. One-way ANOVA with Newman-Keuls correction for multiple comparisons was performed. Letters denote statistically significant
differences (n = 3 lanes per cell line, p < 0.05)
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diffuse fluorescence throughout the cytoplasm indicating
inhibition of autophagy. In contrast, Beclin-1 knockdown
had no effect on puncta formation in the presence of
Akti-1/2 (Fig. 5a).
Expression of eGFP-tagged LC3B can also be used in
a functional readout of autophagic degradation to fur-
ther confirm the relocalization of the fluorescent LC3B
signal. During autophagy, proteolytic enzymes destroy
processed LC3 (LC3-II) that is inserted into the inner
autophagic membrane. However, the relative stability of
eGFP protects it from a similar fate, and therefore, the
abundance of solitary eGFP on immunoblot can be
interpreted as a functional readout of autophagic deg-
radation [35]. We utilized this assay in spheroids since
their three-dimensional architecture precludes routine
live-cell fluorescence microscopy. OVCAR8-eGFP-LC3
cells were cultured to form spheroids, causing an
increase in free eGFP and thus implying induction of
autophagy (Fig. 5b). This elevated level of free eGFP
was undiminished in cells subjected to Beclin-1 knock-
down but was blocked by ATG5 and/or ATG7 knock-
down (Fig. 5b).
Our findings were confirmed in the ascites-derived,
early-passage cell line iOvCa147-E2, which was also
transfected with siRNAs against BECN1, ATG5, and
ATG7. As before, significant Beclin-1 knockdown (p <
0.05) could not disrupt autophagy induced by Akti-1/2
(Fig. 6a, Additional file 5: Figure S3C) or spheroid forma-
tion (Fig. 6a, Additional file 5: Figure S3D). However, au-
tophagy could be blocked by knockdown of ATG5 and
ATG7, or their combination (Fig. 6a).
Finally, we wished to assess the contribution of Beclin-
1 to basal autophagy (i.e., not induced by Akti-1/2 or
spheroid formation). Again, Beclin-1 knockdown yielded
Fig. 4 Beclin-1 knockdown does not block autophagy induction in ovarian cancer cell lines with low, intermediate, and high levels of Beclin-1
expression. CaOV3, OVCAR8 eGFP-LC3, and HeyA8 cells were each transfected with control siRNA (siNT) or siRNA targeting BECN1, ATG5, ATG7, or
ATG5 + 7 and cells seeded to adherent or non-adherent culture. a Adherent cells were allowed to attach overnight, treated with DMSO or Akti-1/
2 (5 μM) the next day, and harvested 24 h later to generate protein lysates. Immunoblots were performed for indicated proteins. b Spheroids
(along with a parallel adherent culture transfected with control siRNA) were harvested 24 h after seeding to non-adherent culture. Protein
lysates were generated and immunoblot performed for indicated proteins. Immunoblots depicted are representative of duplicate experiments
Correa et al. Journal of Ovarian Research  (2015) 8:52 Page 9 of 15
significantly reduced protein levels (p < 0.05), yet no
change in LC3-II in SKOV3 [Additional file 4: Figure
S2B (‘A’ lanes) and Additional file 6: Figure S4B], HeyA8
(Additional file 6: Figure S4A, C), and iOvCa147-E2
(Additional file 6: Figure S4A, D) cells; whereas basal
levels of LC3-II were decreased by knockdown of ATG5,
ATG7, or both (Additional file 4: Figure S2, Additional
file 6: S4A).
Interestingly, we noted a trend toward slightly increased
LC3-II levels upon Beclin-1 knockdown in multiple lines,
but this was subtle and of unclear significance. Regard-
less of this, in no instance did Beclin-1 knockdown
yield corresponding decreases in LC3-II, as described
above.
These data reveal that the capacity of ovarian cancer
cells to undergo autophagy in vitro is not tied to their
expression of the canonical autophagy regulatory protein
Beclin-1. In fact, efficiently knocking down Beclin-1 in
cell lines with low, intermediate, or high endogenous
expression had no effect on autophagy induction or
basal levels of this process.
Beclin-1 knockdown reduced ovarian cancer cell viability
without altering levels of autophagy or apoptosis
Despite a lack of effect on autophagy, we observed that
efficient Beclin-1 knockdown in iOvCa147-E2 cells
(Fig. 6b) caused significant decreases in cell viability
(Fig. 6c,d). In adherent cells counted using Trypan Blue
exclusion, a 30 % reduction in viable cell number was
observed relative to controls (Fig. 6c). Similarly, spheroid
cells exhibited a 50 % reduction in viability as a result of
Beclin-1 knockdown (Fig. 6d). Likewise, in HeyA8
cells, Beclin-1 knockdown significantly reduced viabil-
ity by 30 % in adherent cells and by 15 % in spheroids
(Additional file 7: Figure S5). Therefore, our findings
in iOvCa147-E2 and HeyA8 cells demonstrate the dis-
pensability of Beclin-1 for autophagy induction, yet
Fig. 5 Autophagy induction in OVCAR8-eGFP-LC3B cells is unaffected by Beclin-1 knockdown. OVCAR8-eGFP-LC3 cells were transfected with
control siRNA (siNT) or siRNA targeting BECN1, ATG5, ATG7, or ATG5 + 7 and seeded to adherent or non-adherent culture. a Adherent cells were
allowed to attach overnight and treated with DMSO or Akti-1/2 (5 μM) the next day. Images were captured 24 h post-treatment using an
Olympus IX70 inverted microscope and ImagePro software. A portion of the siBECN1 image was expanded to clearly show an abundance of
fluorescent puncta around the nucleus (n). Scale bar: 50 μm. b Transfected cells seeded to non-adherent culture were harvested 24 h following
seeding, protein lysates generated, and immunoblot performed for indicated proteins. An anti-GFP antibody was used to detect fused and free
eGFP protein. Images and immunoblot are representative of duplicate experiments
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suggest a possible role for this this protein in contrib-
uting to ovarian cancer cell viability.
Since Beclin-1 is also known to regulate apoptosis
independent of its role in autophagy (reviewed in [36]), we
postulated that its importance in maintaining iOvCa147-
E2 cell viability could involve anti-apoptotic mechanisms.
To test this, we performed luminescence-based Caspase
3 & 7 activity assays to assess apoptotic activity upon
Beclin-1 knockdown. In both adherent (Fig. 6e) and
spheroid cells (Fig. 6f ), however, no significant increase
in apoptosis induction was observed. This result was
confirmed by using a commercially available antibody
array specific for apoptosis-related proteins; this approach
did not reveal an obvious and significant alteration in
apoptotic pathway protein abundance associated with
reduction in Beclin-1 levels (Additional file 8: Figure S6).
Discussion
Beclin-1 has gained notoriety due to its role in mediating
autophagy and its role as a tumor suppressor in genetically
modified mice. Furthermore, BECN1 localizes to the long
Fig. 6 Beclin-1 knockdown reduces cell viability without altering autophagy or apoptosis. a iOvCa147-E2 cells were transfected with control siRNA
(siNT) or siRNA targeting BECN1, ATG5, ATG7, or ATG5 + 7 and cells seeded to adherent or non-adherent culture. Adherent cells were allowed to
attach overnight, treated with DMSO or Akti-1/2 (5 μM) the next day, and harvested 24 h later to generate protein lysates. Spheroids (along with
a parallel adherent culture transfected with control siRNA) were harvested 24 h after seeding to non-adherent culture. Immunoblots were
performed (n = 3 repeated experiments) with a representative blot depicted (unrelated, intervening lanes cropped). b iOvCa147-E2 cells
were transfected with control siRNA (siNT) or siRNA targeting BECN1 and immunoblot performed to verify Beclin-1 knockdown in adherent
cells (96 h post-transfection). c Viable cells were also counted at this time using Trypan Blue exclusion and normalized to control. Bars: Mean ± SEM (n = 3,
*p < 0.05). d In spheroid cultures, viability was assessed using the CellTiter-Glo assay (7 days post-transfection and 72 h post-seeding to non-adherent
culture). Cell viability data are normalized to controls. Bars: Mean ± SEM (n = 3, *p < 0.05). e Apoptosis was quantified using a Caspase 3/7 activity assay in
adherent cultures at 96 h post-transfection. f Transfected cells were then seeded to non-adherent culture and apoptosis quantified in spheroids at indicated
time points. Caspase 3/7 activity data were normalized to controls. Bars: Mean± SEM (n = 3)
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arm of chromosome 17, a region that sees a high frequency
of monoallelic loss in high-grade serous ovarian cancer
(HGSC). The present study has demonstrated that Beclin-1
protein expression is maintained in spite of prevalent
single-copy loss. On further investigation, however, knock-
down of Beclin-1 protein did not diminish autophagy
induction: both non-pharmacologic and pharmacologic
stimuli (spheroid formation and AKT inhibition, respect-
ively) induced autophagy despite significantly decreased
Beclin-1 levels, implying a decoupling of Beclin-1 from
autophagy regulation. Knockdown did reduce cell viability
without inducing apoptosis, suggesting that in HGSC,
Beclin-1 may in fact perform important autophagy- and
apoptosis-independent functions. This work is the first
to describe retained Beclin-1 protein expression in
hemizygous tumors and to systematically assess Beclin-
1-independent autophagy in ovarian cancer. Our find-
ings move beyond those of prior studies, providing
functional data that challenges the accepted under-
standing of Beclin-1 in autophagy regulation.
Our description of spheroid-associated autophagy also
brings together novel concepts pertaining to ovarian
cancer metastasis. The concept of dormancy in ovarian
cancer spheroids (characterized by cellular quiescence)
has previously been demonstrated by our group and
others [37, 33, 38]. Separately, the concept of autophagy
as an essential feature of dormancy in ovarian tumor
xenografts was described in a seminal publication from
Bast’s group [25]. Our demonstration of autophagy in
spheroids unifies these two concepts for the first time in
ovarian cancer, begging the question of whether autoph-
agy may be another critical feature contributing to the
dormant phenotype of spheroids. It will be of interest to
determine the extent to which autophagy is required for
spheroid dormancy and whether autophagy-modulation
in the clinical setting could impact disease progression.
A novel finding of this study is Beclin-1 protein
expression in 398 HGSCs, despite 76 % of these tumors
harboring single-allele loss of BECN1. It is in keeping
with recent immunohistochemical analyses of Beclin-1
expression that have demonstrated robust staining in
ovarian carcinomas [27] greater than that seen in benign
tumors or normal ovary [39, 40]. None of these studies,
however, evaluated Beclin-1 protein expression in ovar-
ian tumors with respect to gene copy-number as we
have done using TCGA datasets.
We initially hypothesized that the maintenance of
Beclin-1 expression underlined its importance for
autophagy in ovarian tumor cells. Yet surprisingly, we
discovered that knockdown of Beclin-1 had no effect on
autophagy induction. Such a discovery is not without pre-
cedent, since evidence of Beclin-1-independent autophagy
has been emerging and is documented in neuronal
[41, 42], macrophage [43], and breast cancer cells [44].
Even in ovarian cancer, Beclin-1-independent autoph-
agy has been reported in the context of non-canonical
stimuli such as arsenic trioxide [31] and prolactin re-
ceptor antagonism [45]. Our study, however, represents
the first effort to systematically address Beclin-1-
independence in early-passage, ascites-derived ovarian
cancer cells as well as established ovarian cancer lines
selected for their differing BECN1 gene copy-number
as well as mRNA and protein expression. Moreover, we
demonstrate Beclin-1-independent autophagy as a re-
sult of both a pharmacologic (AKT inhibition) as well
as a novel non-traditional stimulus (spheroid forma-
tion). It will be important to demonstrate Beclin-1-
independence in an in vivo model of metastatic ovarian
cancer. Nonetheless, our work represents an important
first step, demonstrating this phenomenon in multiple
selected cell lines using molecular techniques that are
best applied in vitro.
The apparent dispensability of Beclin-1 for autophagy
induction in ovarian cancer cell lines and its role in
contributing to cell viability in HeyA8 and iOvCa147-E2
cells suggests that it has other functions in cancer.
Autophagy-unrelated Beclin-1 functions have been
suspected since the first mouse models of its disrup-
tion were generated. Mice with homozygous Becn1 dis-
ruption (Becn1−/−) die by embryonic day 7.5 [46],
whereas Atg5−/− and Atg7−/− mice are able to complete
embryonic development and survive to birth, eventu-
ally succumbing to autophagy insufficiency during the
neonatal starvation period and dying within 24 h [47,
48]. Furthermore, the tumor spectrum of Becn1+/−
mice differs from other mouse models of autophagy
disruption: Becn1+/− mice develop hepatocellular car-
cinomas, lung carcinomas, and lymphomas [9] whereas
tissue-specific deletion of Atg7 or mosaic deletion of
Atg5 led to only benign liver adenomas [49] and never
the hepatocellular carcinomas seen in Becn1+/− mice.
This discordance in both knockout phenotype as well
as tumor spectrum suggests additional functions of
Beclin-1 separate from its role in autophagy. In fact,
evidence for its specific autophagy-independent func-
tions continues to emerge (reviewed in [50]). In com-
plex with Class III PI3K, p150 and other co-factors,
Beclin-1 functions in Toll-Like Receptor-mediated
phagocytosis in macrophages [51], in endocytic deg-
radation of the Epidermal Growth Factor Receptor
(EGFR) and in cytokinesis in HeLa cells [52]. Fremont
et al. also demonstrated a critical role for Beclin-1 in
kinetochore assembly and chromosome congression
that is not only autophagy-independent, but also inde-
pendent of the Class III PI3K and p150 core complex
[53]. Thus, in vitro and in vivo data support Beclin-1’s
non-exclusivity to autophagy regulation, supporting the
idea that its retained expression may fulfill autophagy-
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independent function(s). It will be important to evalu-
ate precisely how this occurs; first by determining its
importance to cancer cell viability, proliferation, and
metastasis. These experiments could uncover novel and
important oncogenic functions of Beclin-1 that are ap-
plicable to other disease sites.
Conclusions
In conclusion, our findings challenge the accepted
relationship between Beclin-1 and autophagy in ovarian
cancer and prompt a re-evaluation of the existing model.
While we cannot exclude the possibility that autophagy
may initially be disrupted by single allele loss of BECN1
to promote ovarian tumorigenesis, we have clearly
shown that Beclin-1 is present in advanced-stage tu-
mors and tumor cells. It is conceivable that initial dis-
ruption of Beclin-1 and autophagy forces adaptation of
the autophagic machinery to no longer depend upon
Beclin-1, yet a role for this protein in maintaining
tumor cell viability may select for its continued expres-
sion. Further study is needed to not only elucidate the
complex and context-dependent roles of Beclin-1 in ovar-
ian and other tumors, but also to understand the often
paradoxical nature of autophagy in cancer biology.
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Additional file 2: Table S2. Summary of TCGA ovarian cancer patient
clinical data (provisional dataset). (XLS 71 kb)
Additional file 3: Figure S1. Ovarian cancer adherent cells and spheroids
undergo autophagic flux. (A) Adherent cultures were subjected to 24h
treatment with Akti-1/2 (5μM) ± Chloroquine (CQ 50μM) pulse in the final 4h
preceding lysis. (B) Lysates were also obtained from parallel spheroid cultures
(24h) ± CQ pulse (final 4h). Immunoblots were
performed for indicated proteins and LC3-II expression quantified relative to
Actin (n = 2 repeated experiments). (PNG 488 kb)
Additional file 4: Figure S2. Beclin-1 knockdown fails to block
autophagy induction in adherent and spheroid cultures of SKOV3 cells.
Adherent SKOV3 cells were transfected with control siRNA (siNT) or siRNA
targeting BECN1, ATG5, or ATG7. (A) Cells were seeded to adherent culture,
allowed to attach overnight, treated with DMSO or Akti-1/2 (5μM) the next
day, and harvested 24h later to generate protein lysates. (B) Spheroids
(along with a parallel adherent culture transfected with control siRNA) were
harvested 24h after seeding to non-adherent culture. Depicted immunoblots
are representative of triplicate experiments. (PNG 735 kb)
Additional file 5: Figure S3. Beclin-1 knockdown significantly reduces
Beclin1 protein but is unable to suppress LC3-II. (A,B) Protein expression
quantification data (Beclin-1 and LC3-II, relative to Actin) from CaOV3,
OVCAR8, HeyA8, and SKOV3 cells were pooled for adherent (A) and
spheroid (B) experiments. Bars: Mean ± SEM (n = 2–3 experiments per cell
line, 4 cell lines pooled. Paired t-test was performed (NS = no significant
difference, *p<0.05, ***p<0.001). (C,D) Expression of Beclin-1 and LC3-II was
quantified in iOvCa147-E2 adherent (C) and spheroid (D) cells. Bars: Mean ±
SEM (n = 3 independent experiments; NS = no
significant difference, *p<0.05, ****p<0.0001). (PNG 246 kb)
Additional file 6: Figure S4. Beclin-1 knockdown fails to suppress basal
levels of autophagy in adherent ovarian cancer cells. (A) Adherent HeyA8
and iOvCa147-E2 cells were transfected with control siRNA (siNT) or siRNA
targeting BECN1, ATG5, ATG7, or ATG5 and ATG7. Cells were re-seeded to
adherent culture and harvested 48h later to generate protein lysates.
Depicted immunoblots are representative of triplicate experiments.
(B,C,D) Protein expression of Beclin-1 and LC3-II was quantified in
unstimulated (B) SKOV3, (C) HeyA8, and (D) iOvCa147-E2 cells. Bars:
Mean ± SEM (n = 3 independent experiments per cell line; NS = no
significant difference, *p<0.05, **p<0.01). (PNG 393 kb)
Additional file 7: Figure S5. Beclin-1 knockdown reduces the viability
of HeyA8 adherent and spheroid cells. Adherent HeyA8 cells were
transfected with control siRNA (siNT) or siRNA targeting BECN1. Cells were
seeded to either adherent or spheroid culture, and 72h later, subjected
to viability assessment using the CellTiter-Glo assay. Bars: Mean ± SEM
(n = 3 independent experiments; *p<0.05, **p<0.01). (PNG 127 kb)
Additional file 8: Figure S6. Apoptosis-related protein expression is
largely unaltered in adherent and spheroid cells upon Beclin-1 knockdown.
Adherent iOvCa147-E2 cells were transfected with control siRNA (siNT) or
siRNA targeting BECN1. Cells were seeded to either adherent or spheroid
culture, and 24h later, protein lysates were harvested and apoptosis arrays
processed as per manufacturer’s protocol. Bars: Mean ± SD of duplicate array
dots. (PNG 208 kb)
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